Completed PHASE3 INTERVENTIONAL 2-arm NCT00732615

Use of NPSP558 in the Treatment of Hypoparathyroidism (REPLACE)

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Investigate the Use of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH[1-84]) for the Treatment of Adults With Hypoparathyroidism

Sponsor: Shire

Conditions Hypoparathyroidism

Interventions NPSP558 Placebo

Updated 8 times since 2017 Last updated: May 13, 2021 Started: Dec 18, 2008 Primary completion: Sep 28, 2011 Completion: Sep 28, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Hypoparathyroidism and is currently completed. Shire leads this study, which shows 8 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Sep 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Sep 2021 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Dec 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shire

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aarhus, Denmark , Boston, United States , Budapest, Hungary , Calgary, Canada , Chicago, United States , Cincinnati, United States , Detroit, United States , Florence, Italy , Greenville, United States , Halifax, Canada and 21 more locations